Stock listing
Shanghai:688046 GemPharmatech Co., Ltd. (药康生物) 股价
Follow GemPharmatech Co., Ltd. into a list and get an email when it puts out news.
Share price · SSE:688046
¥26.88 CNY -3.03 (-10.1%)
Close on Nov 20, 2026
- Day range
- ¥26.81 – ¥28.71 CNYNov 20, 2026
- Volume
- 6.24M sharesNov 20, 2026
- Market cap
- ¥11.03B CNYAt the close on Nov 20, 2026 · price × 410.2M shares outstanding
- 52-week range
- ¥12.89 – ¥43.47 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥339.9M CNYMedian day 9.92M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SSE:688046 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥26.88 | -3.03 | -10.1% | ¥28.11 | ¥28.71 | ¥26.81 | 6,240,804 | |
| ¥29.91 | -2.29 | -7.1% | ¥32.22 | ¥32.85 | ¥29.51 | 5,792,049 | |
| ¥32.20 | +0.81 | +2.6% | ¥31.60 | ¥33.29 | ¥31.11 | 5,688,651 | |
| ¥31.39 | -1.08 | -3.3% | ¥31.67 | ¥32.40 | ¥31.01 | 3,541,442 | |
| ¥32.47 | -2.03 | -5.9% | ¥34.05 | ¥34.19 | ¥32.00 | 6,219,451 | |
| ¥34.50 | +0.60 | +1.8% | ¥33.98 | ¥35.13 | ¥33.11 | 6,606,035 | |
| ¥33.90 | -0.01 | 0.0% | ¥33.90 | ¥33.99 | ¥32.44 | 6,315,059 | |
| ¥33.91 | +0.35 | +1.0% | ¥34.51 | ¥35.23 | ¥33.26 | 6,199,830 | |
| ¥33.56 | +0.86 | +2.6% | ¥32.80 | ¥35.81 | ¥32.80 | 7,073,229 | |
| ¥32.70 | -0.65 | -1.9% | ¥31.01 | ¥35.68 | ¥31.00 | 10,001,842 | |
| ¥33.35 | +2.72 | +8.9% | ¥30.04 | ¥33.69 | ¥30.03 | 12,229,270 | |
| ¥30.63 | +3.48 | +12.8% | ¥27.25 | ¥30.72 | ¥26.53 | 9,879,199 | |
| ¥27.15 | -2.64 | -8.9% | ¥29.23 | ¥29.70 | ¥26.70 | 10,104,335 | |
| ¥29.79 | +0.51 | +1.7% | ¥29.13 | ¥30.25 | ¥27.80 | 10,402,066 | |
| ¥29.28 | +0.60 | +2.1% | ¥28.48 | ¥32.32 | ¥26.64 | 13,498,745 | |
| ¥28.68 | -0.31 | -1.1% | ¥29.02 | ¥29.98 | ¥28.33 | 8,195,549 | |
| ¥28.99 | +2.41 | +9.1% | ¥26.89 | ¥29.62 | ¥26.89 | 8,362,544 | |
| ¥26.58 | -0.67 | -2.5% | ¥27.73 | ¥27.82 | ¥26.38 | 6,518,299 | |
| ¥27.25 | -0.29 | -1.1% | ¥27.24 | ¥27.84 | ¥26.49 | 7,828,105 | |
| ¥27.54 | -0.24 | -0.9% | ¥27.03 | ¥27.87 | ¥25.43 | 8,372,782 | |
| ¥27.78 | -1.43 | -4.9% | ¥29.51 | ¥29.88 | ¥27.40 | 6,130,110 | |
| ¥29.21 | -1.04 | -3.4% | ¥31.35 | ¥31.35 | ¥29.13 | 6,853,357 | |
| ¥30.25 | +1.75 | +6.1% | ¥28.40 | ¥30.67 | ¥27.61 | 9,951,282 | |
| ¥28.50 | -0.50 | -1.7% | ¥29.00 | ¥29.76 | ¥26.42 | 12,639,663 | |
| ¥29.00 | -2.70 | -8.5% | ¥32.32 | ¥33.30 | ¥28.62 | 12,129,589 | |
| ¥31.70 | -0.05 | -0.2% | ¥30.54 | ¥33.85 | ¥30.54 | 10,624,369 | |
| ¥31.75 | -0.97 | -3.0% | ¥32.95 | ¥32.95 | ¥31.73 | 7,372,695 | |
| ¥32.72 | -0.94 | -2.8% | ¥32.80 | ¥33.48 | ¥30.00 | 12,691,810 | |
| ¥33.66 | -0.97 | -2.8% | ¥34.64 | ¥35.95 | ¥33.44 | 10,346,975 | |
| ¥34.63 | -0.87 | -2.5% | ¥35.23 | ¥35.50 | ¥32.90 | 8,833,429 | |
| ¥35.50 | -2.44 | -6.4% | ¥36.97 | ¥37.24 | ¥35.18 | 11,633,500 | |
| ¥37.94 | +2.96 | +8.5% | ¥34.86 | ¥38.78 | ¥34.83 | 16,589,266 | |
| ¥34.98 | -0.08 | -0.2% | ¥34.73 | ¥37.17 | ¥34.73 | 9,101,558 | |
| ¥35.06 | -0.86 | -2.4% | ¥35.99 | ¥36.40 | ¥34.95 | 7,640,264 | |
| ¥35.92 | -2.69 | -7.0% | ¥38.54 | ¥38.61 | ¥35.80 | 13,507,718 | |
| ¥38.61 | +0.88 | +2.3% | ¥37.72 | ¥40.30 | ¥37.08 | 12,226,088 | |
| ¥37.73 | +0.95 | +2.6% | ¥35.85 | ¥39.48 | ¥35.85 | 12,079,773 | |
| ¥36.78 | +1.50 | +4.3% | ¥36.00 | ¥37.45 | ¥35.50 | 12,473,420 | |
| ¥35.28 | +0.73 | +2.1% | ¥34.91 | ¥36.79 | ¥34.39 | 12,464,129 | |
| ¥34.55 | +0.50 | +1.5% | ¥33.83 | ¥36.55 | ¥33.60 | 12,956,946 | |
| ¥34.05 | +1.68 | +5.2% | ¥32.21 | ¥34.30 | ¥31.91 | 12,427,163 | |
| ¥32.37 | -0.45 | -1.4% | ¥32.79 | ¥33.35 | ¥32.18 | 8,493,688 | |
| ¥32.82 | +3.03 | +10.2% | ¥29.31 | ¥33.29 | ¥29.31 | 13,776,660 | |
| ¥29.79 | -0.78 | -2.6% | ¥30.57 | ¥30.58 | ¥28.91 | 7,859,626 | |
| ¥30.57 | -1.05 | -3.3% | ¥31.34 | ¥31.34 | ¥30.04 | 7,449,418 | |
| ¥31.62 | -0.86 | -2.6% | ¥32.29 | ¥32.55 | ¥31.07 | 9,655,570 | |
| ¥32.48 | +1.26 | +4.0% | ¥31.31 | ¥32.90 | ¥30.61 | 14,526,982 | |
| ¥31.22 | +0.51 | +1.7% | ¥30.66 | ¥31.22 | ¥30.51 | 5,244,082 | |
| ¥30.71 | -1.03 | -3.2% | ¥32.20 | ¥32.20 | ¥30.43 | 8,380,179 | |
| ¥31.74 | +0.62 | +2.0% | ¥31.76 | ¥31.85 | ¥30.80 | 8,772,303 | |
| ¥31.12 | -0.05 | -0.2% | ¥31.31 | ¥31.95 | ¥30.61 | 9,626,465 | |
| ¥31.17 | -0.74 | -2.3% | ¥31.91 | ¥31.97 | ¥30.50 | 10,486,621 | |
| ¥31.91 | -0.59 | -1.8% | ¥31.50 | ¥32.16 | ¥31.21 | 8,728,657 | |
| ¥32.50 | -0.87 | -2.6% | ¥33.01 | ¥33.75 | ¥31.80 | 10,086,830 | |
| ¥33.37 | +0.21 | +0.6% | ¥33.16 | ¥33.57 | ¥32.40 | 10,011,380 | |
| ¥33.16 | -1.33 | -3.9% | ¥34.83 | ¥35.80 | ¥32.53 | 12,175,906 | |
| ¥34.49 | +0.61 | +1.8% | ¥32.68 | ¥35.05 | ¥32.40 | 17,083,578 | |
| ¥33.88 | -0.47 | -1.4% | ¥35.04 | ¥35.78 | ¥32.82 | 16,768,860 | |
| ¥34.35 | -2.35 | -6.4% | ¥35.13 | ¥35.80 | ¥33.36 | 23,446,175 | |
| ¥36.70 | +0.70 | +1.9% | ¥37.55 | ¥38.80 | ¥35.28 | 30,625,123 |
- Ticker
- Shanghai:688046
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Shanghai
- Currency
- CNY
What changed lately
Latest news release · Nov 19, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Departure of Key Technician
Latest news
(688046)"GEMPHARMATECH CO., LTD."Announcement on Departure of Key Technician
Nov 19, 2026
Closed ¥26.88 (-10.1%) on Nov 20, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Acquisition of 80% Equity Interest in Nanjing Bymybio Biotechnology Co., Ltd.
Nov 17, 2026
Closed ¥32.20 (+2.6%) on Nov 17, 2026
(688046)"GEMPHARMATECH CO., LTD."Report for Q3 2026
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Resolutions of the 2nd Meeting of the 3rd Board of Directors
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Provision for Asset Impairment for the First Three Quarters of 2026
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Expiration of the Lock-up Period and Satisfaction of Unlocking Conditions for the Reserved Grant under the 2025 Employee Stock Ownership Plan
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Convening the Q3 2026 Performance Briefing
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Completion of the Industrial and Commercial Registration Change and Issuance of a New Business License
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Capital Increase in Wholly-owned Subsidiaries
Oct 29, 2026
Closed ¥28.68 (-1.1%) on Oct 29, 2026
(688046)"GEMPHARMATECH CO., LTD."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
Oct 20, 2026
Closed ¥30.25 (+6.1%) on Oct 20, 2026
GemPharmatech Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 35 in the last 12 months · 57 in all · newest Nov 19, 2026 · oldest 2025
Valuation
P/E 54.4× against a median of 58.0×: 3rd lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥9.92B CNY
- P/E
- 54.4×
- EV/sales
- 10.5×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 4.7×
- Gross margin
- 64.9%
- Operating margin
- 26.3%
- Net margin
- 21.5%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| PolyPeptide Group AG · SIX:PPGN | US$1.62B | US$1.71B | n/a | 4.0× | 34.2× | 4.2× | −5.4% | 0.4× | n/a |
| Personalis, Inc. · NASDAQ:PSNL | US$1.55B | US$1.39B | n/a | 17.3× | n/a | 7.3× | −147.7% | 0.2× | 2.03 |
| Sino Biological Inc. Class A · SZSE:301047 | US$1.45B | US$1.01B | 54.1× | 8.5× | n/a | 1.9× | 22.6% | 0.0× | n/a |
| Qingdao Haier Biomedical Co., Ltd. Class A · SSE:688139 | US$1.41B | US$1.16B | 34.7× | 3.1× | n/a | 2.1× | 10.8% | 0.0× | n/a |
| Median of the others | US$1.75B | US$1.67B | 58.0× | 6.7× | 34.2× | 4.0× | 1.2% | 0.1× | 1.69 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.32 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.49 · 2 analysts
- Revenue, year to Dec 2026
- 964.2M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brandy Wilkinson | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Xiang Gao | Chair of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | Apr 19, 2023 · Before open | −1.1% |
| Q3 2022 | Oct 30, 2022 · After close | +0.1% |
| Q2 2022 | Aug 19, 2022 · After close | +4.7% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 793.4M | 686.8M | 622.2M | 516.5M | 393.8M | 261.9M | 192.7M |
| Cost of revenue | 284.4M | 261.1M | 201.5M | 147.8M | 101.1M | 73.2M | 63.9M |
| Gross profit | 509.0M | 425.8M | 420.7M | 368.7M | 292.7M | 188.7M | 128.8M |
| Research and development | 92.1M | 87.1M | 96.6M | 82.9M | 55.2M | 48.2M | 30.3M |
| Selling, general and administrative | 118.1M | 110.5M | 84.9M | 73.3M | 58.8M | 35.6M | 47.2M |
| Operating income | 182.0M | 122.3M | 166.3M | 171.6M | 150.6M | 97.7M | 49.6M |
| Depreciation and amortization | 88.2M | 84.8M | 53.7M | 39.1M | 28.8M | 16.8M | 7.43M |
| EBITDA | 270.2M | 207.2M | 220.1M | 210.7M | 179.4M | 114.5M | 57.1M |
| Interest expense | 6.08M | 4.30M | 2.76M | 495.5K | 744.9K | 724.0K | 255.1K |
| Income before tax | 164.9M | 119.2M | 161.3M | 173.7M | 143.3M | 91.4M | 46.9M |
| Net income | 142.6M | 109.8M | 158.9M | 164.7M | 124.9M | 76.4M | 34.7M |
| Earnings per share, basic | 0.35 | 0.27 | 0.39 | 0.40 | 0.30 | 0.21 | 0.10 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 486.6M | 701.4M | 560.2M | 421.7M | 293.5M | 524.2M | 221.9M |
| Short-term investments | 757.7M | 467.3M | 637.7M | 791.2M | 205.8M | 26.9M | |
| Receivables | 385.0M | 350.8M | 269.4M | 185.2M | 118.6M | 90.7M | 63.5M |
| Inventory | 73.0M | 54.2M | 47.1M | 49.5M | 30.1M | 17.3M | 12.4M |
| Current assets | 1.75B | 1.71B | 1.66B | 1.47B | 706.9M | 647.2M | 329.0M |
| Total assets | 2.87B | 2.57B | 2.58B | 2.25B | 1.05B | 883.2M | 388.1M |
| Accounts payable | 68.1M | 72.2M | 101.9M | 50.8M | 61.7M | 46.3M | 23.2M |
| Current liabilities | 527.1M | 371.2M | 366.4M | 214.1M | 191.7M | 149.5M | 123.5M |
| Long-term debt | 20.0M | ||||||
| Total liabilities | 637.9M | 437.9M | 452.9M | 276.0M | 268.8M | 225.9M | 147.7M |
| Shareholders' equity | 2.23B | 2.13B | 2.12B | 1.98B | 785.6M | 657.2M | 240.5M |
| Shares outstanding | 410.0M | 410.0M | 410.0M | 410.0M | 410.0M | 360.0M | 360.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 227.0M | 90.3M | 116.6M | 106.0M | 113.3M | 129.8M | 65.1M |
| Capital spending | -105.0M | -113.7M | -205.9M | -190.3M | -89.1M | -167.1M | -45.7M |
| Free cash flow | 122.0M | -23.4M | -89.3M | -84.3M | 24.2M | -37.3M | 19.5M |
| Dividends paid | -61.2M | -80.1M | -17.9M | -283.5K | -680.0K | -672.3K | -235.8K |
| Change in cash | -215.3M | 141.2M | 138.4M | 128.1M | -230.7M | 302.3M | 198.7M |
Filings
All 56 filings
Cap table
Built by 6ix from GemPharmatech Co., Ltd. Class A’s releases
- Common shares
- 410,186,200
- Fully diluted
- 410,186,200
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 410,186,200 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 410,186,200 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brandy Wilkinson | Chief Executive Officer · Since at least Oct 22, 2025 |
| Xiang Gao | Chair of the Board · Since at least Oct 22, 2025 |
Log in to ask 6ix AI your own questions about GemPharmatech Co., Ltd.